R ecently, the Food and Drug Administration granted approval under Humanitarian Device Exemption regulations for use of the Berlin Heart EXCOR Pediatric (EXCOR) ventricular assist device (VAD) 1 based on a prospective, nonrandomized, multicenter, single-arm investigational device exemption (IDE) study assessing the safety and probable benefit of the device. 2 In this trial, EXCOR led to a 90% survival to transplant or weaning off the VAD. Furthermore, the overall rate of serious adverse events was significantly less in the EXCOR group compared with the extracorporeal membrane oxygenation (ECMO) group. 3 What remains unknown is how outcomes in patients who have been bridged to transplantation supported with EXCOR compare with outcomes in children who were transplanted without VAD support. 4 The purpose of this study was to evaluate the outcomes at 1 year after transplant in children bridged with the EXCOR and to compare these outcomes with a contemporaneous group of children in the Organ Procurement and Transplant Network (OPTN) database, who were not on VAD support at the time of transplantation. number of patients in both EXCOR and OPTN groups were diagnosed with congenital heart disease (CHD). These subgroups, as well as those listed as status 1A or 1B, were evaluated. The status 1A designation includes patients who are ventilator dependent, VAD dependent, high-dose inotrope dependent, as well as patients supported with ECMO.
Study Aim
The aim of this analysis was to determine whether pediatric heart transplant patients bridged with EXCOR have different post-transplant outcomes compared with pediatric heart transplant patients not requiring VAD support as a bridge to transplant. Outcomes were measured 1 year after transplantation.
End-organ dysfunction in the EXCOR group was defined as (1) renal dysfunction, estimated by the glomerular filtration rate adjusted for age using the Schwartz formula 6 and categorized as moderately impaired (glomerular filtration rate, 30-99 percentile) or severely impaired (glomerular filtration rate <30% predicted); and (2) hepatic dysfunction, as reflected by the total serum bilirubin level, categorized as moderately increased (0.7-1.1 mg/dL) and severely increased (≥1.2 mg/dL). All clinical and demographic variables for the EXCOR group were collected at the time of EXCOR implantation unless otherwise specified.
Statistical Analysis
Summary statistics are presented as means and SDs with medians and ranges or number (percent). Comparisons within the EXCOR data or comparisons of EXCOR with OPTN were made using the χ 2 or Fisher exact test (if appropriate) for discrete variables. Kaplan-Meier survival data comparisons between EXCOR and OPTN were made, and testing was performed using the log-rank test. Analyses were performed using SAS version 9.2.
Results

Patient Survival and Mortality
Of the 148 patients who received the EXCOR VAD, 113 patients were bridged to transplant, 23 patients died on support, 11 were weaned off the device, and 1 patient was still on VAD support. Of the EXCOR-transplanted patients, 1-year follow-up was available in 106 patients who are the subject of this report. A total of 94 patients from this group were alive, with 12 deaths (11.3%) occurring during this same time interval. Four of the children who died were ≤1 year of age and 8 were >1-year old. Time to death in the EXCOR patients ranged from 1 to 343 days after transplant (median, 143.5 days).
A comparison of mortality after transplant in the EXCOR and OPTN groups is shown in Table 1 . Overall, the outcomes were statistically similar when comparing the number of deaths in the EXCOR group (11.3%; 95% confidence interval [CI]=5.3%-17.4%) with the total number of deaths in the OPTN group (9.5%; 95% CI, 7.7%-11.3%), or the number of deaths in the OPTN patients with status 1A (10.7%; 95% CI, 8.6%-12.8%), or the number of deaths in the OPTN patients on ventilator support (15.9%; 95% CI, 9.5%-22.3%). Notably, however, patients supported with EXCOR did significantly (P<0.001) better than patients bridged to transplant with ECMO, wherein ≈ 40% (95% CI, 27.6%-51.8%) died after transplant. Only the OPTN status 1B patients (3.9% mortality; 95% CI, 0.2%-7.6%) did significantly (χ 2 P=0.04) better than those in the EXCOR group. Mortality in patients with CHD supported by EXCOR (26.1%; 95% CI, 8.1%-44.0%) was ≈10% higher than OPTN subjects with CHD (13.2%; 95% CI, 10.1%-16.3%), as well as OPTN subjects with CHD and status 1A (14.9%; 95% CI, 114.4%-18.5%). However, the outcomes of EXCOR CHD patients with the OPTN cohorts were not statistically significantly different.
Cumulative mortality curves for the various groups are shown in Figures 1A, 1B , and 2. In nearly all instances, the most dramatic increase in mortality occurs early, with the steepest increase notable for the ECMO group (reaching a plateau by ≈75 days after transplant).
Risk Factors for Post-transplant Mortality
A univariate analysis of potential risk factors for post-transplant mortality in the EXCOR patients (n=12) who died is shown in Table 2 . Death after transplant was significantly higher in patients with CHD compared with those with cardiomyopathy or myocarditis (26.1% versus 7.2%, respectively; Fisher exact test P=0.02; Table 2 ). In the survival analysis, those patients who required cardiopulmonary resuscitation within 48 hours before EXCOR implant also had a significantly greater risk of death compared with those who did not (30.0% versus 9.4%; nonsignificant in the univariate analysis Fisher exact test P=0.08). No other factor evaluated proved to be a significant risk factor for post-transplant morality ( Table 2 ). To specifically look at the role of perioperative bleeding in mortality for the CHD group, we looked at the distribution of major bleeding events among EXCOR patients. A major bleeding event occurred in 47 of the 106 EXCOR patients. Of the total, 23 were patients with CHD, and 13 of these (56.5%) had a bleeding event compared with 34 (41.0%) of the remaining 83 non-CHD patients. This difference between the 2 groups was not significant (P=0.18).
Adverse Events and Impact on Mortality
Serious adverse events, as defined by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria 7 recorded during EXCOR support that were evaluated as risk factors for post-transplant mortality, are summarized in Table 3 . Renal dysfunction while on device was the only significant (Fisher exact test P=0.14) event that was more frequent in EXCOR nonsurvivors versus survivors at 12 months after transplant. Occurrence of other serious adverse events, including major bleeding or infection, stroke, or pump change as a result of thrombus, did not have a significant impact on post-transplant mortality.
Causes of Post-transplant Mortality
A breakdown of the causes of post-transplant mortality in EXCOR (n=12) and OPTN (n=90) patients is shown in 
Discussion
The use of VAD to bridge pediatric patients to cardiac transplantation has steadily increased during the past decade. 4 Our study focused on the outcomes of the patients who were bridged effectively to transplantation and demonstrates that the outcomes of patients after transplantation are similar to those not requiring support with a VAD. We found that pediatric patients supported with EXCOR have post-transplant survival similar to OPTN status 1A patients supported either with inotropic therapy or on ventilator support. This finding is consistent with previous observations in adult studies comparing post-transplant survival between VAD and non-VAD ventilator or inotrope-dependent patients. 8 More importantly, children supported with EXCOR have more favorable outcomes compared with those bridged to transplantation with ECMO, which in the past was the primary option for bridging children to transplant. 5 This implies that ECMO support results in inferior outcomes after transplant, consistent with previous reports by Almond and colleagues. 9,10 A recent analysis of a large data set consisting of adult OPTN patients confirmed that all other support pathways besides VAD support, including inotropes, right VAD, and ECMO, increase the risk of post-transplant death. 11 The data presented here show that patients supported with EXCOR have worse outcome than status 1B patients, but the difference is small from clinical perspective. Currently, all pediatric patients supported with a VAD are considered status 1A. The small difference between EXCOR and status 1B patients suggests that perhaps with continued improvements in EXCOR and other pediatric VAD outcomes, status listing for pediatric patients supported with a VAD could change in the future.
The majority of post-transplant deaths in EXCOR patients occur early after surgery, suggesting that the perioperative risk of surgery contributes to these outcomes. This is of interest because prior investigations in the adult setting have shown that extracorporeal VADs like EXCOR are associated with higher mortality within the first 6 months after transplantation, an effect not observed with intracorporeal VADs (even when adjusted for era effect). 12 This time-dependent hazard has also been reported for adult patients supported with extracorporeal devices that survived to 5 years after transplant. 13 Our study duration of 1 year does not allow analysis of such longer-term effects, which could be important if overall longevity of grafts or need for retransplantation is affected by prior VAD support.
In this data set, rejection was the most significant cause of death after transplantation for EXCOR patients. In contrast, post-transplant deaths in the OPTN group were accounted for by multisystem organ failure, graft failure (either nonspecific or primary), and infection, which were absent or a less prevalent cause of EXCOR deaths. The absence of primary graft dysfunction among the EXCOR patients is significant because previous adult studies have shown that paracorporeal and VAD use in adult patients can lead to an increased incidence in primary graft dysfunction. [14] [15] [16] Findings related to rejection after VAD support are often ascribed to potential sensitization from support, although there has been some controversy. 14, [17] [18] [19] Using the OPTN adult data, Arnaoutakis et al 14 demonstrated that device type (continuous flow versus pulsatile, with higher sensitization rates in latter) or levels of panel-reactive antibody activity (>25% defined as high) were not associated with worse mortality. Furthermore, they found that panel-reactive antibody activity did not affect rejection rates in the first year after transplant.
The incidence of rejection (both early and late) for pediatric heart transplant patients has decreased in the current era, especially during the first post-transplant year. 20 This report is the first to suggest increased incidence of rejection-related death after transplant in pediatric heart transplant candidates supported with EXCOR. In the adult setting, VAD support has not been associated with increased incidence of fatal episodes of rejection after transplant. 21 Sensitization in adults has been mostly reported in the setting of long-term support. 19 Most of the EXCOR patients who died from rejection after transplant were supported for a short duration. It is possible, therefore, that this select group represents a presensitized cohort with unique attributes. Unfortunately, our study is limited by a lack of relevant and important data related to risk factors for posttransplant rejection such as preformed reactive antibodies. Pending further investigation, careful analysis of the sensitization status of the pediatric patients should be noted before VAD implantation.
In our study, univariate analysis suggested cardiopulmonary resuscitation within 48 hours of device implant as a significant risk factor for post-transplant mortality. The overall numbers, however, for this, as well as preimplant liver and kidney dysfunction, were too small to reach definitive conclusions. Similar limitation related to the number of events could have accounted for the lack of significance for prior prolonged ECMO support on outcomes, despite a trend in numbers that would suggest otherwise. Alternatively, patients who transitioned from ECMO to VAD or who were salvaged by the device after cardiopulmonary resuscitation are a select group of patients who by definition had to survive to transplantation. Residual end-organ dysfunction, however, could impact the outcome of the survivors. Recently, Engin et al 21 provided a retrospective review of 14 critically ill adult patients, 11 of whom had received EXCOR support, demonstrating improved end-organ function after VAD implantation and before heart transplantation. Therefore, additional studies are needed to address the potential impact of EXCOR on end-organ recovery. Unequivocally, our data demonstrate that diagnosis of CHD continues to be a significant risk factor for less than optimal post-transplant outcomes even when patients are bridged to transplantation with EXCOR. Fan et al 22 had previously demonstrated that CHD diagnosis is a risk factor for in-hospital mortality after VAD implantation in pediatric patients. As well, Almond et al 3 had shown that only a third of the patients with CHD bridged to transplantation with ECMO survive to hospital discharge after transplantation. Clearly, in this cohort of patients, EXCOR when feasible is superior to ECMO. For many of these patients, because of patient size or other anatomic constraints, ECMO is still often used as the primary alternative. Combining postimplant mortality during the waitlist period and mortality after transplantation, children with CHD carry a substantial burden of mortality in the pathway to transplantation as amply demonstrated in International Society of Heart and Lung Transplantation database. Are these results a reflection of additional surgeries done in the hopes of avoiding transplantation and resulting in less than optimal candidates for VAD support (eg, worse renal function), timing of referral for VAD support (eg, after cardiac arrest and initiation of ECMO), or technical challenges posed by underlying complex anatomic substrate? Understanding these nuances would have significant implications in developing strategies (eg, new techniques) to improve outcomes for this cohort (and likely increasing numbers in the future) of patients.
That only 2 of the rejection deaths occurred in patients with CHD as the primary diagnosis suggests that the risk of mortality in this subpopulation is not driven simply by increased incidence of sensitization or preformed antibodies. The steep drop-off on the Kaplan-Meier curves would suggest the risk primarily relates to perioperative mortality and the likelihood these patients have had multiple prior operations with complex anatomy and complex physiologies. Further studies looking specifically at the cause of death among the patients with CHD would be valuable as the first step in improving outcomes for these patients.
There are several other limitations to our study, one of which is that we could not do further subgroup analysis of the patients. For example, although the EXCOR device is clearly superior to support with ECMO, superiority to ventilatory support was not seen. It is conceivable that a certain cohort of patients requiring ventilatory support would be further helped by being on the EXCOR device because such support would allow the children to rehabilitate more effectively than those who remain on the ventilator. Similarly, we do not know how many EXCOR patients were or were not on a ventilator at the 
S30 Circulation
September 10, 2013 time of transplant; thus, we could not separate any increased risk of post-transplant mortality in EXCOR patients on or not on a ventilator at the time of transplant. We also could not evaluate donor organ quality that might be relevant when comparing EXCOR 1A patients with nonsupported 1A patients.
Finally, our analysis was limited to 1 year after transplant; it is conceivable that not enough time has been allotted for observation of effects for some other important factors that require longer follow-up for manifestation (eg, coronary vasculopathy).
In conclusion, our study shows that the EXCOR device support leads to post-transplant survival outcomes similar to those seen among patients not requiring support. Furthermore, post-transplant survival is improved with an EXCOR device compared with post-transplant survival in those bridged with ECMO. Patients with CHD who are bridged to transplantation have an increased risk of mortality after transplantation, regardless of the mode of support. Finally, in the IDE trial, a potential significant cause of mortality for VAD-supported patients after transplantation was related to rejection, a finding that deserves further detailed investigations.
With increasing experience at multiple centers and the potential development of data registries and use of the device in nontrial setting, further insights will be gained into the use of EXCOR as bridge for transplantation and its impact on outcomes after transplantation. The evolution of support technology in the pediatric population, including the upcoming continuous flow devices, will inevitably lead to a paradigm shift in the field of pediatric heart failure and transplantation and likely all aspects of pediatric cardiology and cardiac surgery.
